The Weekly Roundup: March 7-11

ICYMI, this week we had stories on new data on pembrolizumab, Amyrt receiving a Complete Response Letter (CRL) for Oleogel-S10, and more.

POLL: Are Your Patients Struggling to Afford Treatment?

The Mainstream Patient: March 7

This week's edition of the Mainstream Patients features stories about the benefits of face steaming for the skin, doctors that are making hair transplants more accessible to Black patients, and more.

Pembrolizumab Demonstrates Improvement in IIB, IIC Melanoma

Merck announced that pembrolizumab led to significant improvement in distant metastasis-free survival (DMFS) compared to placebo as adjuvant therapy for patients with resected stage IIB and IIC melanoma in the phase 3 KEYNOTE-716 trial.

Vaccine Divide Between Urban and Rural Areas Increasing

Rural areas lag well behind their urban counterparts when it comes to COVID-19 vaccinations.

5 steps to make telehealth work for physicians and patients

There are barriers to telehealth adoption that physicians must overcome to realize the technology’s promise.

Test-to-Treat COVID initiative comes under fire from doctors

Skipping physicians for convenience not the best way for patients to receive care says AMA.

Positive Preclincal Data Seen for VYN201 in Human Skin Model of Vitiligo

VYNE Therapeutics announced positive preclinical data of a lead BET inhibitor reducing melanocyte loss and key inflammatory biomarkers from an ex vivo skin model of vitiligo.

Amyrt Receives FDA Complete Response Letter for Oleogel-S10 to Treat Epidermolysis Bullosa

The company was asked by the FDA to submit additional confirmatory evidence of effectiveness in the treatment of epidermolysis bullosa.

JAK Inhibitors in Atopic Dermatitis: Historical Use and Mechanisms of Action

Focusing on JAK inhibitors, panelists consider the historical use of these agents in atopic dermatitis and their corresponding mechanisms of action.

Topical Ruxolitinib Use in Atopic Dermatitis

A panel of experts review the use of topical ruxolitinib in atopic dermatitis, shedding light on safety and efficacy considerations.

Pointers with Dr Portela: Topical Steroid Withdraw

In this week’s Pointers with Dr Portela, the 208SkinDoc has a discussion with Marvin Rapaport MD, about the potential adverse events that may occur when patients overuse topical steroids. Watch the interview, meant for educational purposes only, to see what they had to say.

What's Happening at the San Diego Dermatology Symposium

Jashin Wu, MD, FAAD, the founder and course director of the 3rd Annual San Diego Dermatology Symposium, offers highlights of the gamechanging topics on the agenda for this in-person conference set for March 11-13, 2022, in San Diego, California. Watch to see more information about the presentations.

Drug Watch: What's Coming in the Rosacea Pipeline

Dermatology Times® interviews editorial board member Richard Gallo, MD, PhD, who dives into what is currently lacking is rosacea patient care, how the new mechanisms of action of these potential treatments will better address current struggles, and more.

I Meant to Code Correctly; Now Could I Go to Jail?

In this month's Legal Eagle, David J. Goldberg, MD, JD, discusses the legal complexities of incorrect medical coding.

Focusing on Toners and Astringents

In this month's Cosmetic Conundrum, Zoe Diana Draelos, MD, discusses the differences between astringents and toners and highlights the ideal persons who should use each product.

Rule 1 for Investing During Volatile Markets: Stick to Your Plan

In this month's financial planning column, the OJM group talks about volatile markets and how to navigate investing in uncertain times.

Sneak Peek into the San Diego Dermatology Symposium

This weekend, March 11-13, 2022, the San Diego Dermatology Symposium (SDDS) will be educating physicians in person. Everything from traditional topics like atopic dermatitis to rare disease such as Stevens-Johnson syndrome will be covered.

Phase 2 Difelikefalin Data for AD to be Presented at AAD 2022

Cara Therapeutics announced that difelikefalin—its treatment for moderate to severe pruritus in atopic dermatitis patients—was selected for a late-breaker presentation at the 2022 American Academy of Dermatology annual meeting.

David Pariser, MD, FACP, FAAD, Joins Vial Dermatology CRO

Vial announced another addition to their CRO with David Pariser, MD, FACP, FAAD.